GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published
ROME–(BUSINESS WIRE)–Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”)... Read more.
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
Tenth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast05 phase 3 trial results Sixteenth Breakthrough... Read more.
Coty Appoints Markus Strobel Executive Chairman and Interim CEO
NEW YORK–(BUSINESS WIRE)–Regulatory News: Coty Inc. (NYSE: COTY) (Paris: COTY) (“Coty” or “the Company”) today announced that Markus Strobel... Read more.
JAB Insurance to Enter UK Life and Pension Market With Acquisition of Utmost Group’s Life and Pensions Business
MIAMI–(BUSINESS WIRE)–JAB Insurance today announced that it has entered into a definitive agreement to acquire from Utmost Group plc its Life and Pensions... Read more.
Cloudfresh Wins 2025 EMEA GitLab Partner of the Year Award for Emerging Markets in Eastern Europe and Israel
PRAGUE–(BUSINESS WIRE)–#Cloudfresh–Cloudfresh, a certified GitLab Select and Professional Services Partner and a global leader in delivering multi-vendor... Read more.
Mitsubishi Electric Invests in Tulip Interfaces And Signs Strategic Alliance Agreement
Will leverage no-code operations platform to strengthen DX solutions for manufacturing and beyond TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation... Read more.
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
MARSEILLE, France–(BUSINESS WIRE)–#immunotherapy–Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and... Read more.
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
– Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute – – Availability of Lunsumio VELO allows treatment aligned to people’s... Read more.
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
French medicines agency ANSM has granted authorization for named patient early access program for GS010/LUMEVOQ®, a gene therapy indicated for the treatment of... Read more.
QAD | Redzone Marks 20 Years in India by Honoring 2025 Champions of Change Driving the Future of Manufacturing
Industry leaders recognized for execution, scale, and measurable outcomes as India emerges as a global engine for manufacturing transformation MUMBAI, India–(BUSINESS... Read more.